Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Cabozantinib and Pembrolizumab in Metastatic Pancreas
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
- Status
- RECRUITING
- Phase
- NA
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- Status
- COMPLETED
- Phase
- PHASE2
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
- Status
- TERMINATED
- Phase
- PHASE1
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2